Oncotarget

Research Papers:

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy

Juan Ma _, Pan Ma, Chenghai Zhao, Xin Xue, Huamin Han, Changzhen Liu, Hua Tao, Weigang Xiu, Jia Cai and Man Zhang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:29480-29491. https://doi.org/10.18632/oncotarget.8784

Metrics: PDF 3160 views  |   HTML 3967 views  |   ?  


Abstract

Juan Ma1,*, Pan Ma2,*, Chenghai Zhao3,*, Xin Xue4, Huamin Han5, Changzhen Liu6, Hua Tao5, Weigang Xiu1, Jia Cai1, Man Zhang1,7

1Department of Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China

2Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

3Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China

4Department of Immunology, China Basic Medical Theory of Chinese Medicine, Academy of Chinese Medical Sciences, Beijing, China

5CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

6Department of Molecular Biology, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China

7Chinese Medical Doctor Association of Lab Medicine, Beijing, China

*These authors have contributed equally to this work

Correspondence to:

Juan Ma, e-mail: [email protected]

Man Zhang, e-mail: [email protected]

Keywords: B7-H3, bispecific antibody, immunotherapy

Received: September 24, 2015     Accepted: March 28, 2016     Published: April 18, 2016

ABSTRACT

Targeting B7-H3 over-expressed tumor cells with anti-B7-H3 monoclonal antibodies inhibits tumor growth. Here we demonstrated the expression of B7 family homologue 3 (B7-H3) in a wide range of human tumor cells and further investigated whether B7-H3 could be served as a target for T-cell mediated immunotherapy against human cancers. The specific cytotoxic activity of activated T cell (ATC) armed with a novel anti-CD3 x anti-B7-H3 bispecific antibody (B7-H3Bi-Ab) against tumor cell was evaluated in vitro and in vivo. In contrast with unarmed ATC, an increase in cytotoxic activity of B7-H3Bi-armed ATC against tumor cells was observed at effector/target (E/T) ratios of 5:1, 10:1, and 20:1. Moreover, B7-H3Bi-armed ATC secreted more IFN-γ, TNF-α and IL-2 than unarmed ATC. Infusion of B7-H3Bi-armed ATC inhibited tumor growth in severe combined immunodeficiency (SCID) xenograft models, along with a significant survival benefit. Therefore, treatment with novel B7-H3Bi-armed ATC will be a promising strategy for current cancer immunotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8784